Menter, A, Korman, N.J., Elmets, C.A., et al. (2011) Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case-Based Presentations and Evidence-Based Conclusions. Journal of the American Academy of Dermatology, 65, 137-174.
https://doi.org/10.1016/j.jaad.2010.11.055

has been cited by the following article:

• TITLE: Interrupted Etanercept Therapy: A New Case Report

  AUTHORS: Waqas S. Abdulwahhab, Alaa S. Mehair

  KEYWORDS: Adherence, Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α), Etanercept, Interrupted Therapy, Psoriasis

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.11 No.2, April 15, 2021

  ABSTRACT: Psoriasis is a chronic, immune-mediated, inflammatory disease with a high prevalence in the general population (2%). The anti-tumor necrosis factor receptor etanercept is Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both continuous and interrupted etanercept therapy is effective and well-tolerated. This report aims to document a new case presentation of psoriasis on intermittent etanercept injection throughout 36 weeks with long-lasting sustained efficacy and no risk factor. Case Report: A 39-year-old adult male patient with long-standing chronic plaque psoriasis for 15 years duration without joint involvement started loading dose treatment of etanercept injection in whom due to his work circumstances not taken maintenance therapy and showed-up at the clinic after 36 weeks from first induction therapy when partial relapse of psoriatic lesions appear in last week with continued improvement when reintroducing loading treatment on followed-up over the next 36 weeks. Conclusion: Intermittent etanercept therapy considers effective for 36 weeks with prolonging sustained efficacy and without adverse effect.